All News

Article

ERS/EULAR guidelines for CTD-related interstitial lung disease

Jack Cush, MD Sep 09, 2025

The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.

Article

COLCHICORT Trial

Jack Cush, MD Sep 09, 2025

The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.

SPRING-SIR Italian registry of systemic sclerosis: 1917 SSc pts, 56% had GI Sx, assoc w/ longer Dz duration, more severe Dz, diffuse SSc, ILD, digital ulcers, telangiectasias, & tobacco. In 211 very early SSc, 41% GI Sxs (most esophageal), w/ puffy fingers, & dyspnea. https://t.co/l2hStwavuu

Where are we now—and where are we going in ILD treatment? 📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE) Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX

Obstructive sleep apnea in USA is expected to rise from 34·3% in 2020 to 46·2%, resulting in 76·6 million OSA cases by 2050. By 2050 there will be more males w/ OSA (~46 milliion) than females (30·4 million), but greater growth in females over the next 30 years. https://t.co/6YZvSusTWf

Multimorbidity predicts flares in rheumatoid arthritis A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates. https://t.co/yGrvDttcEq https://t.co/45LMtvsFor

Multimorbidity predicts flares in rheumatoid arthritis | RheumNow

September to Remember (9.5.2025) Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD. https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q

September to Remember (9.5.2025) | RheumNow

Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts. The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements. #APLAR25 @RheumNow https://t.co/SsUvQIM9Eu

Is it D2T RA or Clinical inertia? Concept introduced by Dr Kaneko, Japanese Keio RA cohort, followed for 5yrs 5% patients not fitting the D2T RA definition have MDA or HDA The drivers of persistent DA in RA: -overestimation of treatment effectiveness -avoidance of treatment https://t.co/0pkDaUFH4R

https://x.com/AurelieRheumo/status/1963820075947081788/photo/1

Interesting data shared by Dr. Sandhya Pulukool on Asian pts with SjD vs. Caucasians: - Younger age of onset except in Japan - Higher female to male ratio @RheumNow #APLAR25 https://t.co/RPM9zI4tVQ

https://x.com/RHEUMarampa/status/1963822089582023024/photo/1

Peter Taylor on Pre-RA: If Pre-RA is too late for interception, shall we start screening general population? We have to remember RA is a RARE disease Pre-test of RA per year per person would be 0.00025% for primary prevention: A needle in a haystack? @RheumNow @APLAR_org https://t.co/LKGtz1P7sl

https://x.com/AurelieRheumo/status/1963813511152463960/photo/1

Peter Taylor describing the range of potential benefits of Interception strategies in Pre-RA: A) From Ideal: full interception B) To Good outcome: stratified intervention based on high risk population for delay/interception C) To ?Beneficial: attenuate severity of established RA https://t.co/6mqA9tV7ME

https://x.com/AurelieRheumo/status/1963808528394793215/photo/1

Prof Takeuchi on DMARDs treatment and regional disparities For similar dose, serum concentration of the polyglutamate (active) form of MTX is much higher in Japanese than US patients And also high levels achieved much quicker in Japanese than US patients This is strong https://t.co/ikp63wWifj

https://x.com/AurelieRheumo/status/1963783418917052503/photo/1

What’s new in RA Pathogenesis in #APLAR25 by Ellen Gravellese Take home message: there is still hope for synovial biopsies to be a biomarker for prediction of response to treatment As a synovial biopsy expert, I am not convinced of this one, but time will tell @APLAR_org https://t.co/EEw5ncKa1r

https://x.com/AurelieRheumo/status/1963776720307425291/photo/1

Can we prevent #rheumatoidarthritis? Dr. Gravallese shares this interesting slide that summarizes the different disease prevention trials in RA…..they have managed to delay disease onset but prevention is still in question. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/qhGYnNL5Ek

https://x.com/RHEUMarampa/status/1963776657229283718/photo/1

📍Smoking, obesity and low Vit D are significant risk factors for Pre-RA. 📍Subdoligranulum arthritogenic strain is a newly described infectious agent implicated in the pathogenesis of pre-RA @RheumNow #ACR25 @rheumarhyme https://t.co/ZzZZlfdKmk

https://x.com/RHEUMarampa/status/1963772715351114060/photo/1

QD Clinic: Rapidly progressive RA ILD - or not? Dr. Richard Conway, a rheumatologist in Dublin, Ireland, discusses whether this case shows rapidly progressing RA-ILD, or not, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/YC8XFiqZmd

Rheumatoid Arthritis ILD Complications https://t.co/gAZCGTwHLB https://t.co/qcMmDuxXYx

https://buff.ly/dQsS8zR

Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD). https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU

Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA | …

🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH

Welcome! You are invited to join a webinar: Future Treatment of ILD. After regi…

Topics

All News

ERS/EULAR guidelines for CTD-related interstitial lung disease

COLCHICORT Trial

Do you get our email newsletter?